Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY Extension: Oral Cladribine in RRMS
NCT00641537Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Feb 2008
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial of cladribine in relapsing-remitting multiple sclerosis (RRMS) (7 arms), sponsored by EMD Serono. Primary endpoints: Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 4 Hematologic and Hepatic Toxicity at 120 weeks, Mean Change From Baseline in Absolute Lymphocyte Count, Platelet, Neutrophils and Leukocytes at 120 weeks and 10 more. Started Feb 2008; status: completed.
02
Drugs
cladribine
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00641537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00641537.